Anondita Medicare Limited (ANONDITA)
Latest quarterly results (H1 FY26)
In its latest reported quarter, H1 FY26, Anondita Medicare's revenue was ₹54.0 Cr, and net profit ₹13.0 Cr; the operating margin was 35.2%.
| H1 FY26 (₹ Cr) | Value | YoY | vs prev. half |
|---|---|---|---|
| Revenue | ₹54.0 | — | — |
| Operating profit | ₹19.0 | — | — |
| Net profit | ₹13.0 | — | — |
| EPS (₹) | 6.77 | — | — |
| Operating margin | 35.2% | — | — |
ANONDITA delivery percentage
NSE end-of-day data for
On Fri, 16 Oct 2026, 71.9% of the ANONDITA shares traded on NSE were taken to delivery, against the stock's own 20-session average of 66.97%. That is close to its usual level. It traded 2.4 times its average daily volume.
Delivery in the last 5 sessions: 67.4% · 65.2% · 56.4% · 60.1% · 71.9%
A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed
📢 Recent Corporate Announcements
The Board of Directors of Anondita Medicare has approved the allotment of 9,58,166 equity shares of face value ₹10 each at an issue price of ₹950 per share on a rights basis. The total fundraise aggregates up to ₹9,102.58 lakhs (₹91.03 crore). Following this allotment, the company's paid-up equity share capital increased from ₹18,08,66,180 (1,80,86,618 shares) to ₹19,04,47,840 (1,90,44,784 shares). The Rights Issue had opened on September 09, 2026, and closed on September 22, 2026.
- Approved allotment of 9,58,166 equity shares of face value ₹10 each at ₹950 per share
- Total capital raised aggregates up to ₹9,102.58 lakhs (approx. ₹91.03 crore)
- Paid-up share capital expanded from ₹18.09 crore to ₹19.04 crore, representing ~5.3% equity dilution
- Rights issue closed on September 22, 2026, and allotment finalized on September 24, 2026
The Board of Directors of Anondita Medicare has approved the allotment of 9,58,166 equity shares of face value ₹10 each at an issue price of ₹950 per share on a rights basis. The total fundraise aggregates up to ₹9,102.58 lakhs (₹91.03 crore). Following this allotment, the company's paid-up equity share capital increased from ₹18,08,66,180 (1,80,86,618 shares) to ₹19,04,47,840 (1,90,44,784 shares). The Rights Issue had opened on September 09, 2026, and closed on September 22, 2026.
- Approved allotment of 9,58,166 equity shares of face value ₹10 each at ₹950 per share
- Total capital raised aggregates up to ₹9,102.58 lakhs (approx. ₹91.03 crore)
- Paid-up share capital expanded from ₹18.09 crore to ₹19.04 crore, representing ~5.3% equity dilution
- Rights issue closed on September 22, 2026, and allotment finalized on September 24, 2026
Anondita Medicare Limited has withdrawn its earlier nullification letter dated September 08, 2026, reinstating the revised Rights Issue parameters. The company confirmed the allotment of 9,58,166 Rights Equity Shares aggregating up to ₹9,102.58 Lakhs (₹91.03 crore) as per the corrigendum dated September 07, 2026. This supersedes the original Letter of Offer dated August 27, 2026, which planned an issue of 9,58,000 shares. All disclosures and submissions for NSE post-allotment in-principle approval will proceed based on the restored 9,58,166 share count.
- Confirmed allotment of 9,58,166 Rights Equity Shares aggregating up to ₹9,102.58 Lakhs
- Withdrew the Nullification Letter dated September 08, 2026, in its entirety
- Restored Corrigendum to the Letter of Offer dated September 07, 2026, adjusting issue size by 166 shares from original 9,58,000 shares
- Filing will form operative basis for In-Principle Approval (Post Allotment) with NSE
Anondita Medicare Limited has announced the schedule for its 3rd Annual General Meeting (AGM) for the financial year 2025-26, to be held on Tuesday, September 29, 2026. The Register of Members and Share Transfer Books will remain closed from September 22, 2026, to September 29, 2026 (both days inclusive). Additionally, Tuesday, September 22, 2026, has been fixed as the cut-off date to determine eligibility for remote e-voting.
- AGM Date: 3rd Annual General Meeting scheduled for Tuesday, September 29, 2026
- Book Closure: September 22, 2026, to September 29, 2026 (both days inclusive)
- Cut-off Date: September 22, 2026 fixed for remote e-voting eligibility
- Financial Year: Pertains to operations for FY 2025-26
Anondita Medicare Limited has nullified Announcement No. 1 of its September 07, 2026 corrigendum relating to its upcoming Rights Issue. As a result, the issue size reverts to the original terms of ₹9,101.00 Lakhs (9,58,000 Rights Equity Shares) at ₹950 per share, instead of the briefly revised ₹9,102.58 Lakhs (9,58,166 shares). The general corporate purposes allocation also reverts to ₹979.98 Lakhs. Revisions regarding trading in lots of 10 and odd-lot arrangements remain effective.
- Rights issue size maintained at ₹9,101.00 Lakhs across 9,58,000 Rights Equity Shares at ₹950 per share
- Nullified earlier revision proposing 9,58,166 shares aggregating ₹9,102.58 Lakhs
- Allocation towards General Corporate Purposes restored to ₹979.98 Lakhs (from ₹981.46 Lakhs)
- Theoretical entitlement stands at 9,58,166 shares based on the Rights Entitlement ratio of 97:1,831 on 1,80,86,618 existing shares
- Rights Entitlements will be traded and allotted in lots of 10 and multiples thereof
Anondita Medicare Limited has issued a corrigendum to its August 27, 2026 Letter of Offer, marginally increasing its proposed Rights Issue size from ₹9,101.00 Lakhs to ₹9,102.58 Lakhs. The total number of Rights Equity Shares to be issued has been revised upwards from 9,58,000 to 9,58,166 shares at an issue price of ₹950 per share based on an entitlement ratio of 97:1,831. Allocation toward General Corporate Purposes is adjusted to ₹981.46 Lakhs, representing 10.78% of the total issue size. Additionally, the company clarified odd-lot liquidity considerations, noting shares trade in lots of 200 on the NSE SME platform whereas rights entitlements trade in lots of 10.
- Rights issue size marginally revised from ₹9,101.00 Lakhs to ₹9,102.58 Lakhs
- Total shares to be issued increased from 9,58,000 to 9,58,166 at an issue price of ₹950 per share
- Rights Entitlement ratio established at 97:1,831 on 1,80,86,618 existing equity shares
- General Corporate Purpose allocation set at ₹981.46 Lakhs (10.78% of issue size)
- Trading lot mismatch noted: NSE SME trading lot is 200 shares, while rights entitlements trade in lots of 10
Anondita Medicare Limited has clarified the odd-lot trading mechanisms for its upcoming Rights Issue of 9,58,000 equity shares on the NSE SME Platform. The total issue size is structured in whole multiples of the standard 200-share market lot, so no aggregate-level odd-lot disposal is required. However, individual Rights Entitlements will trade in lots of 10, meaning post-allotment individual holdings may end up as odd lots. Shareholders holding odd lots (non-multiples of 200) or fewer than 10 REs will need to use off-market transfers or consolidate lots to trade.
- Total Rights Equity Shares to be issued stands at 9,58,000 shares
- Rights Entitlements (RE) will trade in market lots of 10 on the stock exchange
- Company equity shares trade on the NSE SME Platform only in market lots of 200 shares
- Odd lot holdings resulting from allotments cannot be sold via online exchange trading without prior consolidation
Anondita Medicare Limited has issued the notice for its 3rd Annual General Meeting scheduled for September 29, 2026. Key special resolutions include enhancing the limits of material related party transactions with subsidiary Anondita Healthcare & Rubber Products India Limited from ₹60.00 crore to ₹75.00 crore, and with Promoter & MD Mr. Anupam Ghosh from ₹25.50 crore to ₹55.50 crore. The AGM will also consider the adoption of FY26 financial statements and ratify a cost auditor remuneration of ₹60,000.
- 3rd AGM scheduled for Tuesday, September 29, 2026, at 4:00 PM via Video Conferencing.
- Proposed increase in related party transaction limit with subsidiary AHRPIL from ₹60.00 crore to ₹75.00 crore.
- Proposed increase in related party transaction limit with Promoter & MD Anupam Ghosh from ₹25.50 crore to ₹55.50 crore.
- Ratification of ₹60,000 remuneration for Cost Auditor M/s Bahadur Murao & Co for FY27.
Anondita Medicare Limited has been declared the lowest (L1) bidder under Schedule 1 by the Central Medical Services Society (CMSS), Ministry of Health and Family Welfare, Government of India. The tender involves the supply of 8,00,62,000 (over 8 crore) pieces of condoms under the national Family Planning Programme (Tender Ref. CMSS/Proc/2026-27/FP/005). While the exact financial value of the contract was not disclosed, this win represents a major volume order for the company's manufacturing operations.
- Declared L1 bidder under Schedule 1 by Central Medical Services Society (CMSS)
- Tender entails supply of 8,00,62,000 units (8+ crore pieces) of condoms
- Issued under Government of India's Family Planning Programme (Tender dated May 6, 2026)
- Declaration period finalized in August 2026
Anondita Medicare Limited has been declared as the L1 (lowest) bidder under Schedule 1 by the Central Medical Services Society (CMSS), Ministry of Health and Family Welfare, Government of India. The tender is for the supply of 8,00,62,000 (8.0062 crore) pieces of condoms under the Free Supply Family Planning Programme. While the final monetary order value is not disclosed, securing this tender represents a substantial volume win for the company's domestic manufacturing operations.
- Declared L1 bidder under Schedule 1 by Central Medical Services Society (CMSS)
- Tender quantity stands at 8,00,62,000 (8.0062 crore) pieces
- Issued under Ministry of Health and Family Welfare for Family Planning Programme
- Exact monetary contract value not disclosed in the filing
Anondita Medicare Limited has submitted its final Letter of Offer for a Rights Issue of up to 9,58,000 equity shares to raise up to ₹91.01 crore (₹9,101.00 lakhs). The issue price is fixed at ₹950 per share (face value ₹10 plus ₹940 premium) with an entitlement ratio of 97 rights shares for every 1,831 equity shares held. The record date for determining eligible shareholders is September 02, 2026. The issue will open on September 09, 2026, and close on September 22, 2026, with on-market renunciation available until September 11, 2026.
- Rights issue to raise up to ₹91.01 crore (₹9,101.00 lakhs) via 9,58,000 fully paid equity shares
- Issue price set at ₹950 per share (₹10 face value + ₹940 premium)
- Rights ratio established at 97 rights shares for every 1,831 existing shares held
- Record date fixed as September 02, 2026; issue window spans September 09 to September 22, 2026
- Targeted listing of rights equity shares on NSE Emerge platform on or about September 25, 2026
Anondita Medicare Limited has appointed M/s Garg Piyush & Associates, Chartered Accountants (ICAI Reg No. 019331C), as the Internal Auditor for FY 2026-27. The appointment was approved by the Board of Directors at its meeting held on August 27, 2026, following recommendations from the Audit Committee. Established in May 2014, the auditing firm will handle internal audit and compliance processes for the upcoming financial year.
- Appointment of M/s Garg Piyush & Associates as Internal Auditor for FY 2026-27
- Board approval granted on August 27, 2026, based on Audit Committee recommendation
- Auditing firm holds ICAI Registration No. 019331C and was established on May 9, 2014
Anondita Medicare Limited has appointed M/s Garg Piyush & Associates, Chartered Accountants, as the company's Internal Auditor for the financial year 2026-27. The appointment was approved by the Board of Directors on August 27, 2026, upon the recommendation of the Audit Committee. Garg Piyush & Associates, established on May 9, 2014 (ICAI Reg No 019331C), provides audit, assurance, and corporate compliance services. This is a standard corporate governance and compliance update.
- Appointment of M/s Garg Piyush & Associates as Internal Auditor for FY 2026-27
- Board approved appointment on August 27, 2026, following Audit Committee recommendation
- Auditor firm established on May 9, 2014 (ICAI Registration No. 019331C)
Anondita Medicare Limited's Board of Directors has approved the appointment of M/s Mohit Singhal & Associates as Secretarial Auditor for FY 2026-27 during its meeting on August 27, 2026. The appointment was made based on the recommendation of the Audit Committee. Lead auditor CS Mohit Singhal has over 10 years of practice experience in corporate laws and compliance. This represents a routine statutory governance filing with no impact on operations or revenue.
- Appointment of M/s Mohit Singhal & Associates as Secretarial Auditor for FY 2026-27
- Approved by the Board of Directors on August 27, 2026, following Audit Committee recommendation
- Lead auditor CS Mohit Singhal has 10+ years of experience in corporate law and governance
Anondita Medicare Limited announced the outcome of its Board of Directors meeting held on August 27, 2026. The Board approved the appointment of M/s Mohit Singhal & Associates as Secretarial Auditor, M/s Garg Piyush & Associates as Internal Auditor, and M/s Bahadur Murao & Co. as Cost Auditor. All appointments are for the financial year 2026-27, based on recommendations from the Audit Committee.
- Board approved auditor appointments at its meeting held on August 27, 2026
- M/s Mohit Singhal & Associates (COP no. 15995) appointed as Secretarial Auditor for FY 2026-27
- M/s Garg Piyush & Associates (ICAI Reg No 019331C) appointed as Internal Auditor for FY 2026-27
- M/s Bahadur Murao & Co. (Firm Reg No 08) appointed as Cost Auditor for FY 2026-27
Financial Performance
Revenue Growth by Segment
In H1 FY26, the company reported total revenue from operations of INR 54.10 Cr. While specific percentage splits between male and female condom segments are not disclosed, the revenue is driven by the flagship 'COBRA' brand and manufacturing for domestic and international markets.
Geographic Revenue Split
Currently, the company has a strong domestic presence, particularly in North India. With the new MDSAP certification, it is targeting five major international jurisdictions: Australia, Brazil, Canada, Japan, and the United States, which represent high-value regulated markets.
Profitability Margins
The company maintains high profitability with an EBITDA margin of 35.49% and a PAT margin of 24.06% as of H1 FY26. These margins are supported by a quality-driven, compliant production model and own manufacturing facilities.
EBITDA Margin
EBITDA margin stands at 35.49% (INR 19.20 Cr) for H1 FY26. This high margin reflects efficient manufacturing operations and the premium positioning of its contraceptive products.
Capital Expenditure
The company is undergoing automation-led capacity enhancement to support scalable growth; however, the specific historical and planned expenditure in INR Cr is not disclosed in the available documents.
Operational Drivers
Raw Materials
Not disclosed in available documents (typically involves latex and silicone for condom manufacturing).
Capacity Expansion
The company is implementing automation-led capacity enhancement to scale production. Current installed capacity in units is not specified, but the expansion is designed to meet increased demand from five new international markets (USA, Japan, Brazil, Canada, Australia).
Manufacturing Efficiency
The company follows a quality-driven, compliant production model with ongoing automation initiatives to improve throughput and maintain the 35.49% EBITDA margin.
Strategic Growth
Growth Strategy
Growth will be achieved through a three-pronged strategy: 1) Global expansion into five regulated markets (USA, Brazil, Canada, Japan, Australia) via MDSAP certification; 2) Product innovation through patented female condom products; and 3) Institutional growth via UN qualification and government procurement agencies.
Products & Services
Male and female condoms, including patented female condom variants.
Brand Portfolio
COBRA
New Products/Services
Patented female condom products are being positioned for scalable growth; expected revenue contribution percentage is not disclosed.
Market Expansion
Targeting entry into Australia, Brazil, Canada, Japan, and the USA following the MDSAP certification received in January 2026.
Strategic Alliances
The company is seeking improved acceptance by global distributors, institutions, and government procurement agencies following its regulatory milestones.
External Factors
Industry Trends
The industry is shifting toward harmonized regulatory standards (like MDSAP) and increased demand for female-centric contraceptive options. Anondita is positioning itself by aligning with ISO 13485:2016 standards to compete in stringent global markets.
Competitive Landscape
Competes with global and domestic condom manufacturers; competitive positioning is enhanced by meeting the unified regulatory requirements of multiple global regulators.
Competitive Moat
The company's moat is built on: 1) Regulatory barriers to entry (MDSAP certification is difficult to obtain); 2) Intellectual property (patented female condoms); and 3) 25 years of leadership expertise under Mr. Anupam Ghosh. These are sustainable as they require significant time and technical compliance to replicate.
Macro Economic Sensitivity
Demand for contraceptive products is generally resilient to GDP fluctuations, but export revenue will be sensitive to global healthcare spending and international trade policies.
Consumer Behavior
Increasing global focus on reproductive health and female-led contraceptive choices supports demand for the company's patented female condom range.
Geopolitical Risks
Trade barriers or changes in medical device import regulations in the USA, Japan, or Brazil could impact the success of the export strategy.
Regulatory & Governance
Industry Regulations
MDSAP Certification under ISO 13485:2016 from DQS Medizinprodukte GmbH; ongoing UN qualification process for institutional sales; compliance with medical device standards in Australia, Brazil, Canada, Japan, and the USA.
Risk Analysis
Key Uncertainties
The primary uncertainty is the speed of market penetration in the five newly accessible international jurisdictions and the successful completion of the UN qualification process.
Geographic Concentration Risk
Currently high concentration in North India, with a strategic pivot toward international exports to diversify geographic risk.
Third Party Dependencies
Dependency on DQS Medizinprodukte GmbH for maintaining MDSAP certification and on global distributors for international market entry.
Technology Obsolescence Risk
Mitigated by ongoing automation-led capacity enhancement and R&D into patented products.
